Expanded Access for New Investors!In 2016 Spectral's PMX was granted an Expanded Access designation by the FDA.
This used to be called a Compassionate Approval, meaning it could be used for Sepsis patients on compassionate grounds. Yes the FDA saw the benefits and granted this approval which I am 99.9% sure is still in place as Dr. Kellum mentioned it in a recent presentation.
Combine Expanded Access, with 250,000 RWE uses, a 100% safety profile, excellent segmented Euphrates data, the Tigris trial greatly exceeding expectations, major league trial sites and the Breakthrough Designation and it demonstrates PMX is a LOCK for approval!!
Yes it is a LOCK!